Regeneron Pharmaceuticals Inc
REGN
Detailliertes Diagramm anzeigen
560.000USD
-8.200-1.44%
Handelsschluss 09/12, 16:00（ET）Kurse um 15 Minuten verzögert
59.58BMarktkapitalisierung
13.36KGV TTM
Intraday
1m
30m
1h
D
W
M
D
Heute
-1.44%
5 Tage
-2.33%
1 Monat
-1.05%
6 Monate
-16.03%
Seit Jahresbeginn
-21.38%
1 Jahr
-51.45%
Detailliertes Diagramm anzeigen
TradingKey Aktien-Score
Währung: USD Aktualisiert：2025-09-12Wichtige Einblicke
Die Fundamentaldaten des Unternehmens sind relativ schwach. Seine Bewertung wird als angemessen bewertet angesehen,und die institutionelle Anerkennung ist sehr hoch. In den letzten 30 Tagen haben mehrere Analysten die Aktie mit einer Kaufen bewertet. Trotz einer schwachen Aktienmarktperformance zeigt das Unternehmen starke Fundamentaldaten und technische Indikatoren. Der Aktienkurs bewegt sich seitwärts zwischen den Unterstützungs- und Widerstandsniveaus, was ihn für schwankungsorientiertes Trading geeignet macht.
Aktienbewertung
Widerstand & Unterstützung
Keine Daten
Radar Chart
Aktueller Preis
Vorher
Analysten-Ziel
Basierend auf insgesamt
28
Analysten
Kaufen
Aktuelles Rating
730.349
Kursziel
+30.42%
Aufwärtspotenzial
Hinweis: Analystenbewertungen und Kursziele werden von LSEG ausschließlich zu Informationszwecken bereitgestellt und stellen keine Anlageberatung dar.
Unternehmens-Highlights
HöhepunkteRisiko
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
performance_growth_high
performance_growth_high_desc%!(EXTRA string=16.67%)
valuation_underestimated
valuation_underestimated_desc%!(EXTRA string=PE, string=13.42)
institutional_decreasing_position
institutional_decreasing_position_desc%!(EXTRA string=99.72M, string=2.00%)
institutional_hold%!(EXTRA string=The Vanguard)
institutional_hold_desc%!(EXTRA string=The Vanguard, string=9.37M)
Nachrichten
Bald gibt es mehr Neuigkeiten, bleiben Sie dran...
Finanzindikatoren
EPS
Keine Daten
Gesamteinnahmen
Keine Daten
Unternehmen
Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.
BörsenkürzelREGN
UnternehmenRegeneron Pharmaceuticals Inc
CEODr. Leonard S. Schleifer, M.D., Ph.D
Websitehttps://www.regeneron.com/
Verwandte Finanzinstrumente
-0.12%
-0.25%
-0.85%
-1.90%
-2.80%
-2.75%
+1.05%
-2.24%
-2.81%
-3.98%
-1.30%
-0.71%
-2.82%
-1.16%
-0.61%
-1.57%
+0.03%
-1.60%
-0.57%
-0.15%
